Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...

Reclassifying HFmrEF as a stable phenotype aims to reduce therapeutic inertia and GDMT underuse driven by heterogeneous labeling and clinician uncertainty. Pathobiologic overlap with HFrEF supports ...

Adults who have heart failure with a left ventricular ejection fraction of 40% or more face a high risk of hospitalization for heart failure and cardiovascular death. People who have heart failure ...

The researchers of a recent British Medical Journal paper reviewed heart failure diagnosis and management data. Heart failure has led to considerable health and financial burdens globally, especially ...

When the heart struggles to pump efficiently, a cascade of events unfolds. Fluid accumulates in the lungs and extremities. Breathing becomes labored. Simple activities like climbing stairs or carrying ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Advanced heart failure is when heart failure progresses to the most severe stage. When you have advanced heart failure, your blood pressure, blood flow, kidney and liver function, exercise capacity, ...

The combination of sacubitril and valsartan appeared superior to enalapril in the first randomized trial to generate high-quality evidence to support a drug treatment specifically for patients with ...

Belgrade, Serbia – 17 May 2025. An artificial intelligence-enabled electrocardiogram-based algorithm performed well in the early detection of heart failure among healthcare-seeking individuals in ...